Pharmacotherapy for gastric and intestinal cramping pain: ‎ current and emerging therapies

医学 科克伦图书馆 临床试验 梅德林 重症监护医学 随机对照试验 内科学 政治学 法学
作者
Taraneh Mousavi,Mohammadhossein Sharifnia,Shekoufeh Nikfar,Mohammad Abdollahi
出处
期刊:Expert Opinion on Pharmacotherapy [Informa]
卷期号:24 (18): 2021-2033 被引量:1
标识
DOI:10.1080/14656566.2023.2265830
摘要

ABSTRACTIntroduction Acute gastrointestinal cramping pain (GICP) is a debilitating condition that affects many people worldwide, significantly reducing their quality of life. As such, prompt treatment is crucial.Areas covered This article will explore relevant literature from databases such as PubMed, Scopus, Google Scholar, Cochrane Library, and Web of Science. Additionally, we searched ClinicalTrials.gov and the WHO ICTRP database for the latest clinical trials.Expert opinion Consensus dictates that antispasmodics such as hyoscine-N-butyl bromide and mebeverine should be the primary treatment for GICP. If these prove ineffective, patients can switch to an antispasmodic with a different mode of action or add acetaminophen/NSAIDs for more severe cases. Currently, several antispasmodics are undergoing clinical trials, including drotaverine, alverine, pinaverium, otilonium bromide, fenoverine, tiropramide, otilonium bromide, trimebutine, and peppermint oil. Well-designed head-to-head studies are necessary to evaluate current antispasmodics' safety, efficacy, pharmacokinetic, and pharmacoeconomics profiles. Recent studies have shown that fixed-dose combinations of antispasmodics + NSAIDs or two different antispasmodics can improve patient compliance and synergistically reduce GICP. Therefore, it is recommended that the global availability and accessibility of these products be enhanced.KEYWORDS: Antispasmodiccrampsfunctional gastrointestinal disordergastric painhyoscinemebeverinespasmspasmolytic Article highlights Dealing with gastric and intestinal cramping pain (GICP) can be difficult due to the lack of a clear definition and global guidelines for managing this symptom, as well as poorly designed clinical studies.However, there are effective treatments available. The first line of treatment for GICP is antispasmodics such as hyoscine-N-butyl bromide and mebeverine. If these do not work, trying a different antispasmodic with another mechanism of action and adding NSAIDs/acetaminophen can be helpful.For centrally-mediated GICP, low-dose tricyclic antidepressants (TCAs) or selective serotonin reuptake inhibitors (SSRIs), benzodiazepines, or melatonin may be helpful.There are also new therapies emerging for managing GICP, like selective 5-HT3 antagonists, guanylate cyclase-C receptor agonists, fixed-dose combinations of antispasmodics and NSAIDs, or two antispasmodics.To improve the management of GICP and enhance the quality of life for those affected, we recommend conducting well-designed clinical studies and economic evaluations comparing the efficacy, safety, pharmacokinetic, and pharmacoeconomic profiles of available antispasmodics, developing GI-restricted, multi-target antispasmodics, or improving the pharmacokinetic profile of current agents.Declaration of interestThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Reviewer disclosuresPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.Additional informationFundingThis paper was not funded.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
搜集达人应助过时的起眸采纳,获得10
刚刚
similar发布了新的文献求助10
1秒前
1秒前
baibaibai发布了新的文献求助10
2秒前
yyq完成签到,获得积分10
3秒前
Cinderella完成签到,获得积分10
3秒前
Daisy发布了新的文献求助10
4秒前
4秒前
果粒橙980应助可问春风采纳,获得10
5秒前
耿瑶完成签到,获得积分10
5秒前
5秒前
5秒前
清脆的冰露完成签到,获得积分20
6秒前
善学以致用应助nimo采纳,获得10
6秒前
6秒前
哇咔咔完成签到,获得积分10
6秒前
6秒前
不学无墅完成签到,获得积分10
7秒前
周水吉吖完成签到 ,获得积分10
7秒前
Carlo完成签到,获得积分10
8秒前
LSD发布了新的文献求助10
9秒前
王楷楷发布了新的文献求助10
9秒前
隐形曼青应助77采纳,获得10
9秒前
共享精神应助玛莎机采纳,获得30
9秒前
9秒前
9秒前
10秒前
11秒前
11秒前
星辰大海应助whiteandpink098采纳,获得20
13秒前
英勇冰颜完成签到,获得积分10
13秒前
门板完成签到,获得积分10
14秒前
Kuta完成签到,获得积分10
14秒前
啊哈哈发布了新的文献求助10
14秒前
雪白胡萝卜完成签到,获得积分10
15秒前
苏卿应助hehe采纳,获得10
15秒前
dean发布了新的文献求助10
15秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Mechanistic Modeling of Gas-Liquid Two-Phase Flow in Pipes 2500
Kelsen’s Legacy: Legal Normativity, International Law and Democracy 1000
Handbook on Inequality and Social Capital 800
Conference Record, IAS Annual Meeting 1977 610
Interest Rate Modeling. Volume 3: Products and Risk Management 600
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3546979
求助须知:如何正确求助?哪些是违规求助? 3123961
关于积分的说明 9357531
捐赠科研通 2822555
什么是DOI,文献DOI怎么找? 1551574
邀请新用户注册赠送积分活动 723561
科研通“疑难数据库(出版商)”最低求助积分说明 713801